1 88

Cited 0 times in

진행성 간암에서 전신 요법

Other Titles
 Systemic Therapy in Advanced Hepatocellular Carcinoma 
Authors
 최혜진 
Citation
 Journal of the Korean Liver Cancer Study Group (대한간암연구회지), Vol.11(1) : 33-39, 2011 
Journal Title
 Journal of the Korean Liver Cancer Study Group  (대한간암연구회지) 
ISSN
 1598-6314 
Issue Date
2011
Abstract
Understanding the mechanism of hepatocarcinogenesis has provided the opportunity to evaluate the efficacy of molecularly targeted agents in HCC. Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic, and Raf kinase inhibitory effects, and it is the first new agent to consistently prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). The success of sorafenib is a milestone for systemic therapy of HCC, shifting the paradigm of systemic treatment to molecular targeted agents. Many novel agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are under clinical development. This review attempts to summarize the current status and future perspectives of systemic therapy in HCC.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/95081
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
최혜진(Choi, Hye Jin)
사서에게 알리기
  feedback
Full Text
http://kiss.kstudy.com/journal/thesis_name.asp?tname=kiss2002&key=3009645
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse